Carcinoma of Unknown Primary

histology

Identifier: CI-CAN-00002109
Entity page: /cancer/carcinoma-of-unknown-primary ↗
Edges: 9,401

Neighbours: 15 genes21 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Carcinoma of Unknown Primary approved for …APPROVED_FORderived15 of 57show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Adenocarcinoma of the Breast	—	approved	Breast Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for	Fluorouracil

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RET Mutation SelpercatinibFDA US 2020-05-086 active / 7 trials
Curatedlevel Asensitivity· support 3civicObservedRET altered in 2.6% (68 / 2,653 cases, largest of 2 cohorts)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T SelpercatinibFDA US 2020-05-086 active / 7 trials
Curatedlevel Asensitivity· support 2civicObservedRET altered in 2.6% (68 / 2,653 cases, largest of 2 cohorts)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
EGFR G719A Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L861Q Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR S768I Afatinib3 active / 13 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-1726 active / 44 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.9% (104 / 2,653 cases, largest of 12 cohorts)Regulatoryapproved for Pancreatic Adenocarcinoma (2 approval records)context: Pancreatic Adenocarcinoma
BRCA1 Loss-of-function OlaparibFDA US 2017-08-1726 active / 44 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA1 altered in 2.9% (77 / 2,653 cases, largest of 3 cohorts)Regulatoryapproved for Pancreatic Adenocarcinoma (2 approval records)context: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 0 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Carcinoma of Unknown Primary altered in cohorts of …ALTERED_INderived15 of 1,064show all (up to 200)
← altered in cohorts of	COL7A1 450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	GLB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PLXNB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRIP 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCDC51 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDC25A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CELSR3 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FBXW12 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHATL 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	IP6K2 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NCKIPSD 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PFKFB4 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PRKAR2A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTH1R 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SCN5A 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →

Carcinoma of Unknown Primary investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 325show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 347 trials (162 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	347	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 270 trials (98 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	270	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 221 trials (90 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	221	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 218 trials (89 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	218	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 195 trials (85 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	195	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 189 trials (14 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 184 trials (69 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	184	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 177 trials (48 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	177	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 160 trials (41 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	160	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 152 trials (67 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 114 trials (28 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 114 trials (33 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 108 trials (54 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	108	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 107 trials (39 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 102 trials (60 active) · roll-up of the cancer and its descendants	—	—	Carcinoma of Unknown Primary	102	Observed	clinicaltrials	graph →

Carcinoma of Unknown Primary studied in …STUDIED_INderived10 of 7,955show all (up to 200)
→ studied in	NCT00646022recruiting Natural History of Familial Carcinoid Tumor · condition mapped ALIAS · 7,955 trials mapped (2,699 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04086485Phase 1/Phase 2 · recruiting Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04644770Phase 1 · active not recruiting A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 7,955 trials mapped (2,699 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05540925completed Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma · condition mapped ALIAS · 7,955 trials mapped (2,699 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 7,955 trials mapped (2,699 active)	—	—	High-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →